Business Description
Rani Therapeutics Holdings Inc
NAICS : 541713
SIC : 2833
2051 Ringwood Avenue, San Jose, CA, USA, 95131
Description
Rani Therapeutics Holdings Inc is a clinical stage biotherapeutics company advancing technologies to enable the development of orally administered biologics. The company has developed the RaniPill capsule, a proprietary and patented platform technology, intended to replace subcutaneous or IV injection of biologics with oral dosing.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 93.05 | |||||
| Equity-to-Asset | 0.46 | |||||
| Debt-to-Equity | 0.02 | |||||
| Debt-to-EBITDA | -0.02 | |||||
| Piotroski F-Score | N/A/9 | |||||
| Altman Z-Score | 34.85 | |||||
| Beneish M-Score | -1.55 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History |
|---|
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 52.92 | |||||
| 9-Day RSI | 50.32 | |||||
| 14-Day RSI | 49.87 | |||||
| 6-1 Month Momentum % | -26.85 | |||||
| 12-1 Month Momentum % | -30.75 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 26.29 | |||||
| Quick Ratio | 26.29 | |||||
| Cash Ratio | 25.95 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History |
|---|
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Operating Margin % | -3068.89 | |||||
| Net Margin % | -1021.88 | |||||
| ROA % | -18.7 | |||||
| ROIC % | -786.58 | |||||
| ROC (Joel Greenblatt) % | -1261.25 | |||||
| ROCE % | -60.09 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 108.85 | |||||
| PB Ratio | 5.17 | |||||
| Price-to-Tangible-Book | 5.17 | |||||
| EV-to-EBIT | -2.97 | |||||
| EV-to-Forward-EBIT | -2.77 | |||||
| EV-to-EBITDA | -2.99 | |||||
| EV-to-Revenue | 92.33 | |||||
| EV-to-FCF | -4.74 | |||||
| Price-to-Net-Current-Asset-Value | 5.84 | |||||
| Price-to-Net-Cash | 6.02 | |||||
| Earnings Yield (Greenblatt) % | -33.67 |
Guru Trades
See DetailsEMBED
SAVE
Insider Trades
See DetailsEMBED
SAVE
Gurus Latest Trades with NAS:RANI
Executives
EMBED
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 1.961 | ||
| EPS (TTM) ($) | -1.012 | ||
| Beta | 0 | ||
| Volatility % | 103.61 | ||
| 14-Day RSI | 49.87 | ||
| 14-Day ATR ($) | 1.322065 | ||
| 20-Day SMA ($) | 11.53225 | ||
| 12-1 Month Momentum % | -30.75 | ||
| 52-Week Range ($) | 8 - 36.27 | ||
| Shares Outstanding (Mil) | 24.49 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 9999 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Rani Therapeutics Holdings Inc Filings
| Document | Form | Filing Date | ||
|---|---|---|---|---|
| No Filing Data | ||||